Development in the last 20 years of anti-HER2 targeted therapy for breast cancer.
10.3760/cma.j.cn112139-20220926-00406
- Author:
Bin LIU
1
;
Jina Bin LI
1
;
Ze Fei JIANG
1
Author Information
1. Department of Oncology, the Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100071, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Female;
Breast Neoplasms/drug therapy*;
Trastuzumab;
Breast;
Asian People;
China
- From:
Chinese Journal of Surgery
2023;61(2):89-94
- CountryChina
- Language:Chinese
-
Abstract:
Since trastuzumab was listed and approved for breast cancer in 2002, China has entered a new epoch of targeted therapy. Over the past 20 years, anti-human epidermal growth factor receptor 2 (HER2) targeted therapy for breast cancer in China has experienced the era of single-target, tyrosine kinase inhibitors, double-target and anti-HER2 plus antibody-drug conjugate. Advancement in the anti-HER2 targeted therapy is continuously changing the treatment mode of patients with HER2 positive status and even HER2 low expression, significantly improved their prognosis. In the past 20 years, Chinese scholars have participated in international clinical researches, completed a series of registration studies of imported drugs, developed new drugs with proprietary intellectual property rights, enriched the evidence of clinical research on HER2-targeted therapy, and formed a treatment system with both international standards and Chinese characteristics. In particular, the formulation of the Chinese Society of Clinical Oncology Breast Cancer Guidelines and the Chinese expert consensus on anti-HER2 targeted treatment in breast cancer are the concentrated embodiments of Chinese wisdom.
